Precision Scientific is an innovative translational medicine company with CRO services, dedicated to improvement of patient care. The company has developed a cutting-edge data analytics platform, AIBERT® (AI-driven Big data analytics for Effective Response of cancer Therapy), which is an AI-driven tool focusing on multi omics data mining and predictive algorithms. It provides data-driven solutions for precision oncology research and drug development, including drug target discovery, biomarker identification, indication selection, drug resistance mechanism investigation, and combination therapy recommendation. The company also provides integrated CRO services, including central laboratory full-services, companion diagnostic development and commercialization, regulatory strategy. Precision Scientific has numerous partnerships with world-class biotechnology and pharmaceutical companies, academic and healthcare institutions. It also provides clinical diagnostic services to leading hospitals with the mission of advancing precision medicine.
Xuwo Ji Ph.D.
Founder & CEO
Ph.D. in Bioinformatics, Peking University.
Over 10 years of investment experience in healthcare and life sciences.
Analyst of Healthcare at UBS Securities. Recipient of awards, including: Asia‘s Best Analyst for Healthcare of the Year (2013\2014, Asia Money)
Executive council member of Health Industry Branch of China Health Economics Association (CHEA).
Board member of Future Health Industry Entrepreneurs Association (FHA) and Chair of the Innovation Committee.
Published 5+ papers in high impact journals such as Science Advances and Nature Communications, including first authorship paper published in Nucleic Acids Research.
Distinguished Professor & Deputy Chair, Department of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center.
American Association for the Advancement of Science (AAAS) fellow.
Co-leader of International Cancer Genome Consortium Pan-Cancer Whole Genome Project
Chairman of pan-cancer clinical and predictive science group in the Cancer Genome Atlas (TCGA) project.
Co-chair of Genomic Data Commons (GDC) QC Working Group, National Cancer Institute.
Editorial board member of Cancer Cell, Genome Biology.
Published 170+ papers, 90 in Nature, Cell and sister journals including 12 lead corresponding authorship papers in Cell, Cancer Cell, Nature Biotechnology, Nature Methods, Nature Genetics.
HeadquarterBeijing · Haidian
Strategic decision, operation management, and bioinformatics R&D center
Suzhou Lab & GMP FactoryJiansu · Suzhou
Total 2000 m2 with 1000 m2 IVD manufactory